PMID- 3585450
OWN - NLM
STAT- MEDLINE
DCOM- 19870708
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 5
IP  - 6
DP  - 1987 Jun
TI  - Controlled-release oral morphine sulfate in the treatment of cancer pain with 
      pharmacokinetic correlation.
PG  - 956-61
AB  - The bioavailability and clinical effects of an oral controlled-release morphine 
      sulfate tablet, MS-contin (MSC; Purdue-Frederick, Norwalk, CT) in comparison to 
      an immediate-release (IRMS) preparation were evaluated in normal subjects and 
      cancer patients, respectively. The inherent slow-release character of MSC was 
      confirmed by 2 1/2 X T1/2 absorption rate, one-half Cmax, and twice Tmax relative 
      to IRMS. The T1/2 elimination of the two morphine preparations was similar, 
      demonstrating insignificant risk of MSC accumulation. The difference in the mean 
      number of side effects experienced by the control group per subject was 
      significant (.70 for MSC and 1.26 for IRMS, P = .05) and was consistent with peak 
      plasma morphine attenuation. The cancer patients were initially switched from 
      their previous analgesic to four hourly IRMS and then to MSC at double the dose 
      every eight hours. The majority had their MSC dosing interval lengthened to every 
      12 hours with a decrease in the total daily morphine requirement. While the mean 
      duration on MSC was 20.5 days, many patients were followed poststudy for an 
      extended period with no appreciable development of tolerance. Overall, MSC 
      analgesia and side effects were perceived by the patients as superior compared 
      with prestudy opioids. The advantage of less frequent dosing may lead to 
      improvement of the quality of life of cancer patients.
FAU - Khojasteh, A
AU  - Khojasteh A
FAU - Evans, W
AU  - Evans W
FAU - Reynolds, R D
AU  - Reynolds RD
FAU - Thomas, G
AU  - Thomas G
FAU - Savarese, J J
AU  - Savarese JJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Delayed-Action Preparations)
RN  - 76I7G6D29C (Morphine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Kinetics
MH  - Male
MH  - Middle Aged
MH  - Morphine/*administration & dosage/adverse effects/metabolism
MH  - Neoplasms/blood/*drug therapy
MH  - Pain, Intractable/blood/*drug therapy
MH  - Random Allocation
EDAT- 1987/06/01 00:00
MHDA- 1987/06/01 00:01
CRDT- 1987/06/01 00:00
PHST- 1987/06/01 00:00 [pubmed]
PHST- 1987/06/01 00:01 [medline]
PHST- 1987/06/01 00:00 [entrez]
AID - 10.1200/JCO.1987.5.6.956 [doi]
PST - ppublish
SO  - J Clin Oncol. 1987 Jun;5(6):956-61. doi: 10.1200/JCO.1987.5.6.956.